The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 09, 2024

Filed:

Feb. 14, 2020
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Dean A. Wacker, Yardley, PA (US);

Susheel Jethanand Nara, Mumbai, IN;

Srinivas Cheruku, Bangalore, IN;

Kandhasamy Sarkunam, Hosur, IN;

Firoz Ali Jaipuri, Bengaluru, IN;

Soodamani Thangavel, Krishnagiri, IN;

Rishikesh Narayan, Mumbai, IN;

Subba Reddy Bandreddy, Bangalore, IN;

Srinivas Jogi, Bangalore, IN;

Pavan Kalyan Kathi, Bangalore, IN;

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 233/61 (2006.01); C07D 205/04 (2006.01); C07D 207/06 (2006.01); C07D 271/06 (2006.01); C07D 277/64 (2006.01); C07D 295/04 (2006.01); C07D 309/04 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 413/04 (2006.01);
U.S. Cl.
CPC ...
C07C 233/61 (2013.01); C07D 205/04 (2013.01); C07D 207/06 (2013.01); C07D 271/06 (2013.01); C07D 277/64 (2013.01); C07D 295/04 (2013.01); C07D 309/04 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01);
Abstract

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R; and A, X, X, X, X, Z, Z, R, R, R, R, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.


Find Patent Forward Citations

Loading…